Introduction
Spinal cord injury (SCI) generally results in physical disability, as the pathological events occurring during the acute stages following injury, such as inflammation, apoptosis, oxidative stress and excitotoxicity, can lead to neuronal death and neurological dysfunction. 1, 2 The complex responses induced by SCI include massive inflammatory reactions, the formation of glial scarring and altered intracellular signalling, which could contribute to functional block of descending and ascending neural pathways and the consequent inability to move. 3 Peroxisome proliferator-activated receptor-γ (PPAR-γ) is a ligand-activated transcription factor belonging to the nuclear hormone receptor superfamily 4 and plays an important role in glucose and lipid B Meng, Q Zhang, C Huang et al. Methylprednisolone versus rosiglitazone in acute spinal injury homeostasis. 5 Rosiglitazone and pioglitazone are agonists of PPAR-γ and have been approved for the treatment of type-2 diabetes by the US Food and Drug Administration (FDA). 6 PPAR-γ agonists exhibit anti-inflammatory and antioxidant properties in several animal models of central nervous system injury and disease, such as amyotrophic lateral sclerosis, Parkinson's disease, cerebral ischaemia, haemorrhage and traumatic brain injury. 7 -10 Moreover, the use of a PPAR-γ agonist led to anatomical and locomotor recovery after SCI in rodents in two previous studies. 11, 12 In the present study, the abilities of rosiglitazone and methylprednisolone to improve motor function after experimental SCI were compared. The mRNA and protein expression levels of the neurotrophic factors nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) were measured after SCI in rats in order to clarify the effects of rosiglitazone on neuron repair and development.
Materials and methods

ANIMALS AND TREATMENTS
Adult Sprague-Dawley rats, weighing 200 -250 g, were used in this study. The number of animals used in the experiments was minimized and great care was taken to reduce animal suffering. All surgical procedures were performed under sterile conditions and procedures were approved by the Research Animal Resources and Care Committee of Soochow University.
The rats were randomly divided into four groups: (i) laminectomy without SCI (contusion injury) and without drug treatment (control); (ii) laminectomy with SCI with vehicle (saline) treatment but no drug treatment; (iii) laminectomy with SCI plus treatment with methylprednisolone; and (iv) laminectomy with SCI plus treatment with rosiglitazone. Contusive SCI was induced using a New York University Impactor as described previously. 13 Rats were anaesthetized with pentobarbital (50 mg/kg intraperitoneally) and laminectomy was performed at the T9 − T10 level. After spinal processes T8 and T11 had been clamped to stabilize the spine, the exposed dorsal cord surface was subjected to contusion by producing a weight drop injury with a 10 g rod (2.5 mm in diameter) dropped from a height of 25 mm, and the spinal cord was compressed for 1 min. After surgery, 1.0 ml saline was administered subcutaneously to each animal to replace blood volume loss during surgery. During recovery from anaesthesia, the rats were placed on a warm heating pad and covered with a warm towel. The rats were housed singly in a temperature-controlled room at 27°C for 28 days and were allowed free access to food and water. During this time, their bladders were manually voided twice daily until normal bladder function was regained. Animals given SCI plus rosiglitazone treatment received 2 mg/kg body weight rosiglitazone (Sigma, St Louis, MO, USA) intraperitoneally 5 min, 6 h and 24 h after injury. Animals given SCI plus methyprednisolone treatment received one 30 mg/kg body weight dose of methylprednisolone sodium succinate (Sigma) intraperitoneally immediately after injury. Saline was used as the drug vehicle. Groups of animals were killed 12, 24, 72, 144 and 168 h after injury.
MOTOR FUNCTION ASSESSMENT
Motor function recovery was measured using the Basso, Beattie and Bresnahan scoring system, which uses a 21-point open-field locomotor scale. 14 This scale is based on precise observation of hind limb movements, and on stepping and coordination in an B Meng, Q Zhang, C Huang et al.
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open field. Normal locomotion has a locomotor score of 21 and complete hind limb paralysis has a score of 0. Animals were tested immediately after SCI, on day 3 after SCI or sham surgery (laminectomy only) and then weekly for 4 weeks. Movements were scored for 4 min by two evaluators blinded to the study groups and the mean values for all animals (n = 5) in a group at the same time point were calculated.
REAL-TIME PCR
Real-time polymerase chain reaction (PCR) 15 was used to estimate mRNA transcript levels of the genes encoding NGF (NGF) and BDNF (BDNF). Total RNA was extracted from homogenized spinal cord (caudal, epicentre and rostral) from each rat using RNAiso™ Plus (TaKaRa Biotechnology, Dalian, China). cDNA was prepared from RNA (500 ng) using a DRR014A PrimeScript™ reverse transcription-PCR kit, according to the manufacturer's instructions (TaKaRa Biotechnology). A total of 10 ng cDNA and gene-specific primers were added to SYBR ® Green PCR Master Mix (TaKaRa Biotechnology) and subjected to PCR amplification in a LightCycler ® 480 RealTime PCR System (Roche Applied Science, Penzberg, Germany) using the following programme: one cycle at 50°C for 2 min, one cycle at 95°C for 10 min, then 40 cycles at 95°C for 15 s and 60°C for 1 min. The PCR reactions were conducted in duplicate and amplified transcripts were quantified by the comparative CT method using the gene encoding glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as an internal control. Primer sequences for PCR were: BDNF, 5′-CCC ATG GGT TAC ACG AAG GA-3′(forward), 5′-CCC GAA CAT ACG ATT GGG TAG T-3′(reverse), 88 bp; NGF, 5′-GGA CGC AGC TTT CTA TCC TGG-3′(forward), 5′-CCC TCT GGG ACA TTG CTA TCT G-3′(reverse), 129 bp; GAPDH, 5′-GAC AAC TTT GGC ATC GTG GAA-3′(forward), 5′-ATG CAG GGA TGA TGT TCT GG-3′(reverse), 307 bp.
PROTEIN EXTRACTION AND WESTERN BLOT ANALYSIS
Samples of spinal cord from the injury epicentre and sites caudal and rostral to the epicentre were collected from the rats and homogenized on ice in 10 mM Tris-HCl buffer (pH 7.4), 10 mM ethylene diaminetetra-acetic acid, 30% Triton X-100, 10% sodium dodecyl sulphate (SDS) and saline, using a homogenizer. The supernatants were collected and stored at −80°C. Samples (40 µg total protein per well) were subjected to 10 -14% SDS-polyacrylamide gel electrophoresis and electrotransferred to nitrocellulose membranes. The membranes were then blocked with 10% non-fat dry milk in saline buffer (0.15 M, pH 7.2) for 1 h and incubated with primary antibodies specific to NGF, BDNF and GADPH (Santa Cruz Biotechnology, Santa Cruz, CA, USA) overnight at 4°C. The membranes were washed three times for 10 min in Trisbuffered saline (150 mM saline, 50 mM Tris-HCl, pH 7.5) with 0.1% Tween 20 and incubated with peroxidase-conjugated bovine antirabbit immuno globulin G secondary antibody (1 : 2000) (Santa Cruz Biotechnology) for 60 min at 37°C. Band intensity was determined quantitatively, using Gel-Pro Analyzer™ software (Media Cybernetics, Silver Spring, MD, USA), as a ratio relative to controls for each experiment.
STATISTICAL ANALYSES
The mean ± SE of the data were calculated. Multiple group comparisons of differences in quantitative measurements were made by one-way analysis of variance, followed by Dunnett's t-test. A P-value < 0.05 was considered statistically significant.
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Results
LOCOMOTOR FUNCTION
The score on the modified Basso, Beattie and Bresnahan hind limb locomotor rating scale was 0 (bilateral hind limb paralysis) immediately after spinal cord contusion in all animals subjected to SCI. Rats subjected only to laminectomy had slightly impaired hind limb movement (data not shown). Hind limb movement in rats receiving laminectomy plus contusion injury without drug treatment improved progressively from day 3 (score 1.2) to day 28 (score 6.4). Although there was no noticeable difference between the methylprednisolone-and rosiglitazone-treated groups after a single treatment with rosiglitazone (day 1), the rosiglitazone group had significantly higher locomotor scores than both the methylprednisolone group and the SCI-only group from day 3 onwards (P < 0.05 for each difference at each time point; Table 1 ).
NGF AND BDNF GENE EXPRESSION
Expression of the NGF gene (NGF mRNA levels) peaked 72 h after injury in rats exposed to SCI without drug treatment, expression being significantly greater than in the laminectomy-only group throughout the observation period (P < 0.05), whereas BDNF expression (BDNF mRNA levels) peaked 144 h after injury and values were significantly greater than the laminectomyonly group only from 72 h after injury onwards (P < 0.05) (Fig. 1) .
The NGF mRNA level in all three parts of the spinal cord (caudal, epicentre and rostral) was significantly higher in the rosiglitazone-treated group compared with the other groups at 72 and 168 h (P < 0.05 or < 0.01; Fig. 2 ). The level significantly increased at the lesion epicentre after 24 h in rats subjected to SCI plus contusion without drug treatment (P < 0.01), but not in the rosiglitazone-or methylprednisolonetreated groups, compared with laminectomy-only rats (Fig. 2B) . At the lesion epicentre 72 h after injury, NGF mRNA levels were significantly greater in the group treated with rosiglitazone than in the other groups (P < 0.05). At 168 h, NGF gene expression in the drug-treated groups was significantly lower than at 72 h (P < 0.05) but NGF mRNA remained significantly higher in the rosiglitazone-treated group compared with the other three groups (P < 0.05, Fig. 2B ). Expression of BDNF was non-significantly increased at the lesion epicentre 24 h after injury in animals receiving laminectomy and contusion injury compared with those receiving laminectomy only (Table 2) . Results for the three groups receiving contusion injury indicated that rosiglitazone or methylprednisolone treatment did not significantly affect BDNF mRNA levels at 24 or 72 h, but the BDNF mRNA level was significantly higher in the rosiglitazonetreated group than in the other groups 144 h after injury (P < 0.05).
NGF AND BDNF PROTEIN EXPRESSION
Expression of NGF and BDNF protein in spinal cord homogenates was analysed by Western blotting and found to higher in the spinal cord of rats in the laminectomy with contusion (SCI) group compared with the laminectomy only (control) group at all time points; NGF protein expression peaked 72 h after SCI (P < 0.01 compared with the laminectomy-only group) and BDNF protein expression peaked at 144 h (P < 0.05 compared with the laminectomy-only group) (Fig. 3A) . Rosiglitazone treatment resulted in significantly higher levels of NGF at 72 h and of BDNF at 144 h (P < 0.01 for both neurotrophins versus all other times; Fig. 3B ).
Discussion
Nerve growth factor is a neurotrophic factor B Meng, Q Zhang, C Huang et al. 6 h and 24 h after surgery (SCI + RSG): (A) site caudal to the lesion epicentre; (B) lesion epicentre; (C) site rostral to the lesion epicentre (data presented as mean ± SE of at least eight independent measurements; *P < 0.05 versus other groups; **P < 0.01 versus other groups) 
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for small-diameter sensory neurons, sympathetic neurons in the peripheral nervous system and some neuronal populations in the central nervous system, such as basal forebrain cholinergic neurons. 16 It can protect dorsal root ganglion sensory neurons from cell death and promote sensory axon regeneration. 17, 18 Neurotrophic factors are essential for the development, normal function and survival of septohippocampal cholinergic neurons. 19 In addition to potent neurotrophic activity, these molecules act as protective agents by rescuing neuronal cells after injury to specific neuronal pathways. 20 The present results suggest that NGF may promote the regeneration of sensory fibres into the white matter of the spinal cord.
Previous reports have given conflicting results about changes in NGF levels following SCI. Bakhit et al. 21 found that SCI resulted in an increase in the level of NGF, which reached a maximum 7 days after injury, whereas Bennett et al. 22 showed that NGF levels were significantly decreased for several days after hemisection in the rat spinal cord. In the present study, expression levels of NGF and BDNF were significantly increased in animals receiving laminectomy with contusion compared with those receiving laminectomy only, which suggests a role for neurotrophic factors in spinal cord plasticity and repair 23 Expression of NGF and BDNF has been reported as very low in the normal spinal cord, but increased 1 week after SCI. 24 − 27 Studies have shown that increased intraspinal NGF after SCI is related to: (i) the presence of resident glia and neurons; 28 (ii) the presence of leptomeningeal cells within the pia, and leptomeningeal and Schwann cells, which migrate into the lateral white matter and lesion site; 17, 28 (iii) activated microglia or haematogenous macrophages; 29, 30 and (iv) infiltration of B and T lymphocytes into the SCI to produce and secrete NGF.
31,32
The present study indicated that levels of NGF and BDNF mRNA and protein expression were greatest at the lesion site. Robust expression of NGF mRNA peaked in the injured spinal cord at 72 h and was maintained to at least 168 h after injury, whereas BDNF expression peaked 144 h after injury and was maintained to at least 168 h. The present study indicated that NGF protein plays an important role in the spinal cord after injury and this is probably through its trophic effects on motor neurons and/or on other neurons. 17, 18 The increased levels of NGF and BDNF mRNAs could either lead to the production of more proteins that contribute to axon growth to repair the damaged primary afferent arbour, or cause the spared fibres to respond to the damage.
The ligand-activated transcription factor, PPAR-γ, belongs to the nuclear hormone receptor superfamily. 33 The PPAR-γ protein is a complex of several domains, including a DNA-binding domain (DBD), a ligandbinding domain (LBD) and a D-domain that links the DBD and LBD. 34 The present study is in support with another previously published study 35 in indicating that the gene encoding PPAR-γ is a novel target of the NGF signalling pathway for neuronal differentiation and/or cell survival.
Rosiglitazone and pioglitazone are approved by the US FDA to control blood glucose levels and are used by millions of people with type 2 diabetes. Rosiglitazone has been shown to induce PPAR-γ expression significantly, 10 and rosiglitazone-induced neuroprotection after rodent SCI probably depends on neurotrophic factors and PPAR-γ expression. Rosiglitazone was used in the present study as it is a drug that many patients have already received and it has an established safety record and because the PPAR-γ pathway holds great potential for treating human SCI. 1 Methylprednisolone is the only therapy available to treat patients with acute spinal cord lesions at present. 36 Although recent animal data support its use, improvement following SCI is limited. 37 Nevertheless, many clinics use methylprednisolone to treat human SCI. Methylprednisolone and rosiglitazone may improve anatomical and locomotor recovery after SCI in rodents and they have both been shown to reduce lesions 24 h after injury. 12, 38 The results of the present study suggest that rosiglitazone reduces tissue damage since it significantly increased injury-induced NGF expression 24 h after injury and also increased BDNF expression after injury. Rosiglitazone and methylprednisolone exhibit anti-inflammatory effects, which reduce neutrophil and macrophage infiltration and inhibit secretion of NGF and BDNF by inflammatory cells in the early stages after injury. 12,39 -41 At a later stage after injury, methylprednisolone upregulates NGF and glucocorticoids enhance NGF expression. 42, 43 The results of the present study show that rosiglitazone can upregulate NGF and BDNF expression. Moreover, the effect of rosiglitazone was greater than that
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• Revised accepted 6 April 2011 Copyright © 2011 Field House Publishing LLP of methylprednisolone. These data suggest that rosiglitazone may play a role in modulating NGF and BDNF mRNA expression after SCI.
In conclusion, these findings show that the PPAR-γ agonist, rosiglitazone, enhances endogenous NGF and BDNF levels and suggest that it provides a trophic environment within the lesioned spinal cord. Rosiglitazone may have potential for treating SCI and may be part of the PPAR-γ-activated pathway, which provides neuroprotection. It is, however, unlikely that a single drug will be the answer to the complexity of neuroregeneration and plasticity after SCI.
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